Bg pattern

Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Yttrium Citrate (90Y) Colloidal CIS bio international 37-370 MBq/ml Injectable Suspension

Yttrium Citrate (90Y)

Read all of this leaflet carefully before this medicine is administered to you, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any further questions, ask your nuclear medicine doctor who is supervising the procedure.
  • If you experience side effects, consult your nuclear medicine doctor, even if they are not listed in this leaflet. See section 4.

Contents of the Package Leaflet:

  1. What Yttrium Citrate (90Y) Colloidal CIS bio international is and what it is used for
  2. What you need to know before using Yttrium Citrate (90Y) Colloidal CIS bio international
  3. How to use Yttrium Citrate (90Y) Colloidal CIS bio international
  4. Possible side effects
  5. Storage of Yttrium Citrate (90Y) Colloidal CIS bio international
  6. Package Contents and Additional Information

1. What Yttrium Citrate (90Y) Colloidal CIS bio international is and what it is used for

This medicine is a radiopharmaceutical for therapeutic use only.

Yttrium Citrate (90Y) Colloidal CIS bio international is indicated for the treatment of the knee in cases of synovial hypertrophy (radioisotopic synovectomy) mainly for monoarthritis or oligoarthritis in chronic inflammatory rheumatic diseases, especially rheumatoid polyarthritis.

Administration of Yttrium Citrate (90Y) Colloidal CIS bio international involves receiving a small amount of radioactivity. Your doctor and nuclear medicine doctor have considered that the clinical benefit you will obtain from the procedure with the radiopharmaceutical outweighs the risk of radiation.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before using Yttrium Citrate (90Y) Colloidal CIS bio international

Yttrium Citrate (90Y) Colloidal CIS bio international must not be used:

  • If you are allergic to Yttrium Citrate (90Y) or any of the other components of this medicine (listed in section 6).
  • If you are pregnant or think you may be pregnant.
  • If you are breastfeeding.
  • If you have septic arthritis of the knee.
  • If you have a ruptured synovial cyst.
  • If you have localized infections or skin conditions present in the injection area.

Warnings and Precautions

Be particularly careful with Yttrium Citrate (90Y) Colloidal CIS bio international:

Inform your nuclear medicine doctor in the following cases:

  • If you have an unstable knee joint.
  • If you have had a knee X-ray in the last 8 days.
  • If you have severe bone tissue destruction or
  • Ankylosed joints.
  • If you have significant loss of articular cartilage. Whenever possible, your doctor should avoid administering Yttrium Citrate (90Y) Colloidal CIS bio international to individuals of childbearing potential with reproductive potential.
  • If you are a woman of childbearing potential, before starting treatment, you should begin effective contraception and continue it for several months after treatment.

Children and Adolescents

Tell your nuclear medicine doctor if you are under 18 years old, as administration should be avoided in children during bone growth whenever possible.

Using Yttrium Citrate (90Y) Colloidal CIS bio international with other medicines:

Tell your doctor or nuclear medicine doctor supervising the procedure if you are taking, have recently taken, or may need to take any other medicine, including those obtained without a prescription, as they may affect the quality of the results obtained with Yttrium-90 treatment.

Inform your nuclear medicine doctor if you have recently been administered an X-ray contrast agent. It is recommended to have an interval of at least 8 days after local use of a contrast agent containing EDTA or other chelating agents.

Pregnancy, Breastfeeding, and Fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your nuclear medicine doctor before using this medicine.

You must inform your nuclear medicine doctor before administration of Yttrium Citrate (90Y) Colloidal CIS bio international if there is any possibility that you are pregnant, if you have missed your period, or if you are breastfeeding.

In case of doubt, it is essential to consult your doctor or nuclear medicine doctor supervising the procedure.

If you are pregnant or breastfeeding, you should not receive this medicine.

If you are breastfeeding your child, you should consider delaying the test with this medicine until you have stopped breastfeeding.

Whenever possible, administration of this medicine should be avoided during childbearing age.

Driving and Using Machines

Intra-articular injection of Yttrium (90Y) should be followed by immobilization of the knee, with bed rest for 2 or 3 days to reduce extra-articular migration of the radiopharmaceutical.

Yttrium Citrate (90Y) Colloidal CIS bio international contains 7.4 mg/mL of sodium.

This medicine contains less than 1mmol (23 mg) of sodium per dose; it is essentially "sodium-free".

3. How to use Yttrium Citrate (90Y) Colloidal CIS bio international

There are strict rules for the use, handling, and disposal of radiopharmaceuticals. Yttrium Citrate (90Y) Colloidal CIS bio international will only be used in special controlled areas. This medicine will only be handled and administered by qualified personnel trained to use it safely. These individuals will take special care in the safe use of this medicine and will inform you of their actions.

The nuclear medicine doctor supervising the procedure will decide the amount of Yttrium Citrate (90Y) Colloidal CIS bio international to be used in your case. This will be the minimum amount necessary to achieve the desired effect.

The recommended amount to be administered is normally between 185 and 222 MBq per joint. (Megabecquerel, the unit of measurement used to express radioactivity).

Several joints can be treated simultaneously. In the case of a relapse, re-injection of radioactive colloid into a joint can be performed after a period of 6 months.

The recommended activity range for re-treatment is 111-222 MBq.

After two unsuccessful radiosynovectomies in the same joint, this treatment should not be repeated.

The annual activity should not exceed 444 MBq per knee.

Administration of Yttrium Citrate (90Y) Colloidal CIS bio international and performance of the procedure

The dose is administered by injection directly into the joint to be treated.

Before injection, most of the fluid present in the cavity to be treated should be removed by aspiration.

Duration of the procedure

Your nuclear medicine doctor will inform you of the normal duration of the procedure.

After administration of Yttrium Citrate (90Y) Colloidal CIS bio international, you should:

  • be recommended to have absolute immobilization of the knee, with bed rest for 2 or 3 days. This is to reduce extra-articular migration of the radiopharmaceutical.
  • use effective contraception during several months after treatment.

Your nuclear medicine doctor will inform you if you need to take special precautions after being administered this medicine. Consult your nuclear medicine doctor if you have any doubts.

If you have been administered more Yttrium Citrate (90Y) Colloidal CIS bio international than you should:

Overdose is unlikely because you will receive a single, precisely controlled dose of Yttrium Citrate (90Y) Colloidal CIS bio international by the supervising nuclear medicine doctor. Nevertheless, in the event of an overdose, you will receive appropriate treatment.

If you have any further questions about the use of Yttrium Citrate (90Y) Colloidal CIS bio international, ask your nuclear medicine doctor supervising the procedure.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In approximately 2% of cases, a transient fever reaction may occur within 24 hours of injection.

Allergic reactions have been rarely observed.

In some cases, the injection of radioactive colloid can be painful.

Inflammation may appear in the joint several hours or days after synovectomy. Your doctor may treat this inflammation with analgesic and non-steroidal anti-inflammatory drugs.

There are rare cases where skin necrosis and dark discoloration of the skin occur due to the method of administration.

In rare cases, a secondary joint infection occurs after radiosynovectomy.

Cases of destruction of knee bone tissue have been reported.

Carcinogenic risk (cancer) and leukaemogenic risk (leukaemia; blood cancer affecting white blood cells)

Exposure to ionizing radiation is linked to the induction of cancer and potential development of hereditary defects.

In very rare cases, chronic myeloid leukaemia (one case) and malignant inguinal lymphoma (one case) have occurred. However, the relationship between these pathologies and radiosynovectomy has not been determined with certainty.

Reporting of side effects

If you experience any side effects, consult your doctor or nuclear medicine doctor, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's (AEMPS) online system: www.notificaRAM.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Yttrium Citrate (90Y) Colloidal CIS bio international

You will not need to store this medicine. This medicine is stored under the responsibility of a specialist in appropriate facilities. The storage of radiopharmaceuticals will be carried out in accordance with national regulations on radioactive materials.

6. Package Contents and Additional Information

Composition of Yttrium Citrate (90Y) Colloidal CIS bio international

  • The active ingredient is Yttrium Citrate (90Y). Each mL of injectable suspension contains between 37-370 MBq/mL Yttrium Citrate (90Y) on the calibration date and time.
  • The other ingredients are: sodium chloride solution and sodium hydroxide (to adjust the pH).

Appearance of the product and package contents

This medicine is presented in a glass vial as a white, milky injectable suspension. One vial contains between 1 mL and 10 mL of injectable suspension.

Marketing Authorization Holder and Manufacturer:

CIS bio international

BP 32 - 91192 Gif sur Yvette Cedex

FRANCE

You can request more information about this medicine from the local representative of the Marketing Authorization Holder.

Curium Pharma Spain, S.A.

Avda. Dr. Severo Ochoa, 29

28100-Alcobendas

Phone: 91 4841989

AEMPS Registration Number: 75966

This medicine is authorized in the following countries:

COUNTRY

NAME OF THE MEDICINE

Germany

Yttriumcitrat (90Y) CIS bio international 150 - 370 MBq/ml Injektionssuspension

Belgium

Citrate d‘yttrium [90Y] CIS bio international, suspension colloidale pour injection locale.

Reference: YMM-1

France

Citrate d’yttrium (90Y) CIS bio international, suspension colloïdale pour injection locale

Reference: YMM-1

Hungary

Ittrium[90Y] kolloid CIS bio international szuszpenziós injekció

Reference: YMM-1

Luxembourg

Citrate d'yttrium [90Y], CIS bio international, suspension colloïdale pour injection locale.

Reference: YMM-1

Norway

Yttrium [90Y] colloid CIS bio international, suspension for local injection

Reference: YMM-

Netherlands

[90Y] Yttrium colloïd suspension for intra-articular injection CIS bio international, suspension for injection 37-370 MBq/ml

YMM-1

Portugal

Ítrio [90Y] coloidal, suspensão injectável para administração local, CIS bio international

Reference: YMM-1

Czech Republic

Yttrium-90Y CIS colloid suspension for local injection.

(Koloidní suspenze yttria-90Y pro lokální injekèní aplikaci.)

(Code: YMM-1)

Slovakia

YMM-1

Yttrium-90Y colloid suspension for local injection.

(Koloidná suspenzia yttria-90Y pre lokálnu injekènú aplikáciu.)

Date of last revision of this leaflet: 06/2018

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/

This information is intended only for healthcare professionals:

The complete technical data sheet for Yttrium Citrate (90Y) Colloidal CIS bio international is included as a separate document in the product packaging, in order to provide healthcare professionals with additional scientific and practical information on the administration and use of this radiopharmaceutical.

Please consult the technical data sheet.

Online doctors for Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension

Discuss questions about Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques. For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance. Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults. In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions. Patients commonly seek his care for: 

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (764)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension?
Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension?
The active ingredient in Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension is yttrium (90Y) citrate colloid. This information helps identify medicines with the same composition but different brand names.
Who manufactures Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension?
Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension is manufactured by Cis Bio International. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to Yttrium Citrate (90 Y) Colloidal CIS BIO INTERNATIONAL 37-370 MBq/ml Injectable Suspension?
Other medicines with the same active substance (yttrium (90Y) citrate colloid) include ERBIUM CITRATE (169Er) colloidal CIS BIO INTERNACIONAL 111 MBq/ML INJECTABLE SUSPENSION, Rhenium Sulfide (186Re) Colloidal CIS BIO INTERNATIONAL 148-370 MBq/mL Injectable Suspension, SODIUM IODIDE (I131) CURIUM PHARMA SPAIN 37-7400 MBq CAPSULES. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media